Femasys reported nine-month sales of $1,161,313, down 21.5%, and a net loss of $8,187,810, narrowed from $14,677,582. Cash and cash equivalents stood at $23,913,946 as of September 30, 2026.
FEMY · Femasys Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Latest documents
Femasys completed a $30 million private placement to fund U.S. commercial expansion; overall sales fell 44.5% to $404,597, net loss was $4,564,815, and cash was approximately $23.9 million as of September 30, 2026.
Femasys Inc. appointed John Moorhead as an independent Class II director on October 30, 2026; Kenneth D. Eichenbaum also resigned as a director that day without dispute.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FEMY
this stock
Femasys Inc
|
$9.70M | — | +40.8% | — | 0.6% |
|
ISRG
Intuitive Surgical Inc
|
$149.24B | -24.0% | +20.5% | 52.2 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.68B | — | +8.2% | 95.3 | 3.0% |
|
MDLN
Medline Inc.
|
$49.56B | -10.3% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.60B | -6.0% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 25
Femasys completed a $30 million private placement to fund U.S. commercial expansion; overall sales fell 44.5% to $404,597, net loss was $4,564,815, and cash was approximately $23.9 million as of September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FEMY | -21.7% | -32.9% | -85.3% | -18.3% | -90.3% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -19.4% | -28.2% | -82.3% | -15.2% | -97.7% |